Delving into the Latest Updates on HRS-3802 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action

inhibitors

Mechanism

CDKs inhibitors(Cyclin-dependent kinase inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid NeoplasmMalignant Solid Neoplasm

Inactive Indication-

Originator Organization

Shandong Suncadia Medicine Co., Ltd.

Active Organization

Shandong Suncadia Medicine Co., Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1. Evaluate the safety and tolerability of HRS-3802 monotherapy in patients with advanced malignant solid tumors; 2. Observe the dose-limiting toxicity (DLT) of HRS-3802 monotherapy in patients with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) and recommended dose (RP2D) for Phase II clinical studies.

Start Date14 Jan 2025

Sponsor / Collaborator

Shanghai Hengrui Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with HRS-3802

Login to view more data

100 Translational Medicine associated with HRS-3802

Login to view more data

100 Patents (Medical) associated with HRS-3802

Login to view more data

100 Deals associated with HRS-3802

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	Shandong Suncadia Medicine Co., Ltd.	21 Jan 2025
Malignant Solid Neoplasm	Phase 1	China	Shanghai Hengrui Pharmaceutical Co., Ltd.	14 Jan 2025